Abstract
Background: TONADO and OTEMTO were large, randomised, double-blind, Phase III trials that demonstrated the efficacy of tiotropium/olodaterol (T/O) compared with tiotropium (tio) in COPD.
Aim: We pooled data from TONADO and OTEMTO to investigate the effect on symptoms and lung function of stepping up treatment from tio to T/O in patients who received only tio at baseline.
Methods: TONADO 1+2 (NCT01431274/NCT01431287) were 52-week studies and OTEMTO 1+2 (NCT01964352/NCT02006732) were 12-week studies in patients with COPD with FEV1 <80% predicted in TONADO and ≥30% and <80% predicted in OTEMTO. In this post hoc analysis, we examined the treatment differences between T/O 5/5 µg and tio 5 µg at 12 weeks in patients who received LAMA monotherapy at baseline. 98% of patients treated with LAMA received tio.
Results: At Week 12, T/O increased trough FEV1 from baseline compared with tio (0.074 L; 95% CI 0.033, 0.115; Table). Improvements with T/O versus tio were seen in SGRQ total score (–2.68; 95% CI –5.06, –0.29) and TDI score (1.15; 95% CI 0.56, 1.73). There was a greater likelihood of being a TDI responder and a trend towards a greater likelihood of being an SGRQ responder with T/O compared with tio.
Conclusions: In patients with COPD, optimising lung function by stepping up to T/O from tio led to significant improvements in lung function, health status and breathlessness.
Footnotes
Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA3382.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2019
